{"analyses":[{"ciPctValue":"95","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0002","statisticalMethod":"Chi-squared","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.7","upperLimit":"22.0","value":"17.8"},{"groupId":"OG001","lowerLimit":"33.9","upperLimit":"44.5","value":"39.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"325"},{"groupId":"OG001","value":"329"}],"units":"Participants"}],"description":"PSA response was defined as a ≥ 50% reduction in serum PSA, determined only for patients with a serum PSA ≥ 20ng/mL at baseline, confirmed by a repeat PSA ≥ 3 weeks later.","dispersionType":"95% Confidence Interval","groups":[{"description":"mitoxantrone 12 mg/m\\^2 (Day 1) by intravenous (IV) every 3 weeks, and prednisone 10 mg orally given daily","id":"OG000","title":"Mitoxantrone + Prednisone"},{"description":"cabazitaxel 25 mg/m\\^2 (Day 1) by intravenous (IV) every 3 weeks, and prednisone 10 mg orally given daily","id":"OG001","title":"Cabazitaxel + Prednisone"}],"paramType":"NUMBER","populationDescription":"Prostate Specific Antigen (PSA) response was evaluated only in patients, in the Intention-To-Treat population, with a baseline PSA \\>20ng/mL.","reportingStatus":"POSTED","timeFrame":"from baseline up to 104 weeks (study cut-off)","title":"PSA (Prostate-Specific Antigen) Response","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}